Michael Garrison

Pheon Therapeutics is leveraging two decades of ADC experience to build a novel pipeline of next generation ADCs which offer the potential to treat solid tumors and liquid cancers that do not respond to other treatments. Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development. Using both novel and clinically validated monoclonal antibodies (mAbs) and arming them either with warheads from their proprietary payload platform which boasts a novel mechanism of action or with off-the-shelf linker payload combinations, Pheon is finely attuned to balancing safety and efficacy for each target. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors. The lead agent is expected to reach IND within the next 18 months. Backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies, Pheon Therapeutics has a world class, proven leadership team that brings together the best of ADC engineering, clinical strategy and business expertise. The company has state-of-the-art medicinal chemistry laboratories in London (United Kingdom), and a commercial office in Boston (United States).

Centron Diagnostics Ltd is a King’s College London spin-out company that was set up to develop an accurate, automatic, non-invasive medical device to measure both peripheral blood pressure and central systolic blood pressure. The device uses a novel, patented method that allows both measurements to be performed in one simple operation and will allow this important measurement to be taken into routine clinical use.

Cydar Medical is a global cloud-based software company that provides an integrated solution for planning, navigation and review of surgical procedures powered by Artificial Intelligence.   As leaders in our field, our mission is to transform the way information is provided to clinicians at every stage of the patient pathway to inform better clinical decision-making.   We believe that our clinicians should have the world’s experience at their fingertips, and we will help achieve this vision by using the latest cutting-edge AI technology to enable them to make faster, easier, and safer decisions.  Our first product, Cydar EV Maps, is in use in leading centers across the globe. The system generates a patient-specific 3D map of relevant soft tissue that updates real-time to optimise procedure planning and intra-operative navigation as well as allowing assessment of outcomes. The AI will learn from all procedures globally to provide predictive analytics to assist our clinicians in the OR.

Pheon Therapeutics is leveraging two decades of ADC experience to build a novel pipeline of next generation ADCs which offer the potential to treat solid tumors and liquid cancers that do not respond to other treatments. Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development. Using both novel and clinically validated monoclonal antibodies (mAbs) and arming them either with warheads from their proprietary payload platform which boasts a novel mechanism of action or with off-the-shelf linker payload combinations, Pheon is finely attuned to balancing safety and efficacy for each target. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors. The lead agent is expected to reach IND within the next 18 months. Backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies, Pheon Therapeutics has a world class, proven leadership team that brings together the best of ADC engineering, clinical strategy and business expertise. The company has state-of-the-art medicinal chemistry laboratories in London (United Kingdom), and a commercial office in Boston (United States).

Centron Diagnostics Ltd is a King’s College London spin-out company that was set up to develop an accurate, automatic, non-invasive medical device to measure both peripheral blood pressure and central systolic blood pressure. The device uses a novel, patented method that allows both measurements to be performed in one simple operation and will allow this important measurement to be taken into routine clinical use.

Cydar Medical is a global cloud-based software company that provides an integrated solution for planning, navigation and review of surgical procedures powered by Artificial Intelligence.   As leaders in our field, our mission is to transform the way information is provided to clinicians at every stage of the patient pathway to inform better clinical decision-making.   We believe that our clinicians should have the world’s experience at their fingertips, and we will help achieve this vision by using the latest cutting-edge AI technology to enable them to make faster, easier, and safer decisions.  Our first product, Cydar EV Maps, is in use in leading centers across the globe. The system generates a patient-specific 3D map of relevant soft tissue that updates real-time to optimise procedure planning and intra-operative navigation as well as allowing assessment of outcomes. The AI will learn from all procedures globally to provide predictive analytics to assist our clinicians in the OR.

King’s College London is amongst the top 35 universities in the world and 5th best in the UK (QS World University Rankings 2026), and one of England’s oldest and most prestigious universities.  With an outstanding reputation for world-class teaching and cutting-edge research, King’s maintained its sixth position for ‘research power’ in the UK (2021 Research Excellence Framework).   Kings has more than 33,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and 8,500 staff. Kings has more than 33,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and 8,500 staff. For nearly 200 years, King’s students and staff have used their knowledge and insight to make a positive impact on people, society and the planet. Focused on delivering positive change at home in London, across the UK and around the world, King’s is building on its history of addressing the world’s most urgent challenges head on to accelerate progress, make discoveries and pioneer innovation. Visit the website to find out more about Vision 2029, which sets out bold ambitions for the future of King’s as we look towards our 200th anniversary. World-changing ideas. Life-changing impact: kcl.ac.uk/news